As of February 2022, Allan Rosetzsky has joined GlyProVac’s board of directors! His accession happens in connection with a private placement of 4 mDKK in GlyProVac by a group of business angels located both in Denmark and abroad. Allan Rosetzsky brings to GlyProVac his experience from almost 30 years in biomedical industry as both founder, board member and investor. Allan is a medical doctor by training.
Visit our LinkedIN page for more news!
Antibiotics resistance (AMR) is one of the biggest health challenges of the 21st century, compromising our ability to treat even simple infections. In 2050, 10 million people are expected to die yearly from untreatable microbial infections. New solutions are urgently needed, and vaccines offer a safe alternative to antibiotics.
In GlyProVac ApS we aim to design and develop novel, efficient bacterial vaccine candidates based on our proprietary platform technology BEMAP. Using BEMAP, we have revealed that both benign as well as disease causing bacteria such as E. coli, Pseudomonas aeruginosa and Shigella, extensively modify their proteins with distinct sugar molecules, known as O-linked glycosylations. These modifications drastically influence the topology of the protein and are particularly well recognized by the human immune response.
Based on our paradigm changing discovery we believe inclusion of these modifications are crucial for the development of efficient bacterial vaccines. We are currently establishing PoC for this novel bacterial vaccine concept in the E. coli family (for diarrhoea and urinary tract infection).
Read more about BEMAP and our efforts on our TECHNOLOGY page.
5220 Odense SØ.
Copyright © All Rights Reserved